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Abstract
Background: Truncated variants of Ku86 protein have previously been detected in 86% to 100%
of freshly isolated patient multiple myeloma (MM) cells. Since, the Ku70/Ku86 heterodimer
functions as the regulatory subunit of the DNA repair enzyme, DNA-dependent protein kinase, we
have been interested in the altered expression and function of Ku86 variant (Ku86v) proteins in
genome maintenance of MM.
Results: Although, a number of studies have suggested that truncated forms of Ku proteins could
be artificially generated by proteolytic degradation in vitro in human lymphocytes, we now show
using whole cell immunoblotting that the RPMI-8226 and SGH-MM5 human MM cell lines
consistently express full-length Ku86 as well as a 69-kDa Ku86v; a C-terminus truncated 69-kDa
variant Ku86 protein. In contrast, Ku86v proteins were not detected in the freshly isolated
lymphocytes as was previously reported. Data also indicates that the Ku86v was not generated as
a result of carbohydrate modification but that serine proteases may act on the full-length form of
the protein.
Conclusion: These data confirm that MM cells contain bona fide Ku86v proteins that were
generated intracellularly by a post-transcriptional mechanism, which required proteolytic
processing.
Introduction
Ku80 and Ku70 are two important related family mem-
bers involved in the facilitation of DNA double strand
break repair (DSBR) in association with the DNA repair
enzyme, the catalytic subunit of DNA-dependent protein
kinase catalytic (DNA-PKcs), XRCC4, DNA ligase IV and a
host of other enzymes. Although present in most cells,
Ku86 has been extensively studied in B and T cells due to
its proposed role in the CD40-induced immunoglobulin
(Ig) class switch recombination (CSR) and V(D)J lym-
phocyte antigen recognition/recombination events, both
of which generate transient DNA double-strand breaks.
The importance of this protein in lymphocyte develop-
ment was most notable in Ku86 knockout mice, which
failed to develop mature lymphocytes [1]. There has also
been a strong association with Ku-dependent DNA DSBR
and/or protection from ionizing irradiation-induced DNA
damage [2-6]. Besides its well known role in DNA repair,
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numerous reports have implicated Ku proteins in numer-
ous other cellular processes, including the maintenance of
telomere length, regulation of G2 and M phases of the cell
cycle, regulation of apoptosis and specific gene transcrip-
tion, and regulation of heat shock-induced responses
[7,8].
Although Ku86 and Ku70 are predominantly localized to
the nucleus and the nuclear matrix, it has been found in
other subcellular compartments including the cytoplasm
[9] and cell membranes of numerous cell types [10,11].
The identification of Ku proteins in various compartments
of the cell has led to the identification of putative novel
functions of both Ku86 and Ku70. For example, in multi-
ple myeloma (MM) cells, CD40-induced Ku86 surface
expression resulted in increased cellular adhesion to
fibronectin and bone marrow stromal cells [12] Other
reports indicate that Ku70/Ku86 is found in the cytoplasm
during mitosis and it returns to the nucleus as the cell
enters the G1 phase of the cell cycle [13,14]. Finally, in
colonic tumor cells, translocation of Ku86 from the cyto-
plasm to the nucleus occurs via interactions with a growth
inhibitory tetradecapeptide and thus, Ku86 acts as a puta-
tive somatostatin receptor [15]. Therefore, location of
Ku86 and other members of the DNA repair machinery in
various compartments of mammalian cells may lead to
numerous downstream functional consequences.
There have been a number of reports that indicate Ku86
exists in two forms, an 86 kDa full-length form and a C-
terminal truncated variant form of approximately 69-kDa,
in B cells from the peripheral blood (PB) [16], the acute
promyelocytic leukemia (APL) cell line HL-60 [17], MM
cells [5], as well as senescent fibroblasts [18]. It is unlikely
that the variant protein is a product of alternative splicing
of the Ku86 full length transcripts since shorter mRNAs
have not been found by northern blot analysis [16,17].
Consistent with these findings, a 69-kDa variant of Ku86
was also found in the mitochondria of mammalian cells
[19]. Furthermore, in the above reports, the variant of
Ku86 was still able to bind DNA and associate with Ku70
consistent with the retention of the domains that are asso-
ciated with those functions. Therefore, it is currently
thought that variants of Ku86 are formed as a result of
post-translational modification. It is the nature of this
modification, which has resulted in some controversial
issues regarding the physiological existence of this variant.
Several recent studies have suggested that the Ku86 variant
seen in lymphocytes may be due to cleavage by proteases
induced during biochemical isolation [20-22]. Consider-
ing the increased amount of genomic instability seen in
MM, the disregulated CD40/interleukin-4 (IL-4) pathway
in MM cells [23], and the role of Ku in DNA DSBR and
non-homologous end-joining (NHEJ), we investigated
the presence of Ku86 and its variants in MM cells, and
compared them to T lymphocytes and other cell lines. We
found that unlike human T lymphocytes, the detection of
69-kDa Ku86 (Ku86v-N) variant is not likely due to in
vitro generated protease cleavage. Moreover, we demon-
strate that the full-length, as well as the truncated form of
Ku86 are found in the nucleus, membrane and cytosolic
fractions of resting and CD40-stimulated MM cells.
Finally, we show that intracellular protease inhibition can
prevent the appearance of the Ku86 variant and that the
protease responsible is likely to be a serine protease. The
implications for these findings are discussed.
Methods
Cell culture
RPMI 8226 MM, CESS Epstein-Barr virus (EBV)-trans-
formed normal B cells, K562 chronic myeloid leukemia
(CML), and HL-60 APL human cell lines were all pur-
chased from the American Type Culture Collection
(ATCC, Rockville, MD). The EBV-negative SGH-MM5
human MM cell line (CD10+ CD19- CD20- CD38+
CD40+ CD45+ CD56+ CD138+) was developed in our
laboratory under the Singapore General Hospital (SGH)
Institutional Review Board (IRB) good research practice
guidelines, from a patient with MM using a modified Dex-
ter-type long-term tissue culture system, which was previ-
ously described [23]. All cell lines were cultured in RPMI
1640 medium (Invitrogen, Gibco, Grand Island, NY) sup-
plemented with 10% fetal calf serum (FCS) at 37°C and
5% CO2. Normal PB human T cells were isolated from
buffy coat preparations from healthy donors (after
informed consents were obtained) using Ficoll Hypaque
density gradient centrifugation and CD3 positive mag-
netic bead immunoseparation (MACS columns, Miltenyi
Biotec, GmbH, Gladbach, Germany). For CD40 stimula-
tion conditions, MM cells were optimally stimulated with
soluble CD40 ligand (sCD40L) (Peprotech Inc., Rocky
Hill, NJ) for 4 hrs at 5.0 ng/mL [23].
Cell extract preparation
Fresh whole cell extracts
Cells were washed in phosphate buffered saline (PBS),
pelleted, resuspended in 2× sodium dodecyl-sulfate (SDS)
loading buffer (120 mM Tris HCl pH 7.0, 4% SDS, 720
mM 2-mercaptoethanol (2-ME), 0.01% bromophenol
blue and 20% glycerol), and directly boiled for 10 mins to
inactivate proteases [22] as previously described. Whole
cell extracts were then recovered by centrifugation at
12,000 g for 10 mins and loaded equally and immediately
onto SDS polyacrylamide gel electrophoresis (PAGE) gels.
Conventional whole cell extracts
Cells were lysed in EBC1 lysis buffer (50 mM Tris HCl, pH
8.0, 150 mM NaCl, 0.1% NP-40, 50 mM NaF, 1 mM
Na3VO4, 0.5 µg/ml phenylmethylsulphonylfluoride
(PMSF), and 1 freshly added tablet of protease inhibitorCancer Cell International 2008, 8:4 http://www.cancerci.com/content/8/1/4
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mixture per 50 ml of buffer (Complete™ protease inhibi-
tor tablets; Boehringer Mannheim, Roche Diagnostics
GmbH, Mannheim, Germany). The mixture was then
boiled in SDS sample buffer for 3 to 5 mins before loading
onto SDS-PAGE gels.
Conventional cytosolic protein extracts
Cells were first washed in PBS and lysed in 10 volumes of
the lysis buffer (10 mM Tris HCl pH 7.6, 1.5 mM MgCl2,
10 mM KCl, 0.5% NP-40, 1 mM dithiotretinol (DTT), and
1 freshly added Complete™ protease inhibitor tablet).
Cytosolic protein extracts were recovered by centrifuga-
tion at 1,000 g for 15 mins [20].
Conventional nuclear protein extracts
From the above pellet, cell nuclei were next lysed in 5 vol-
umes of a low-salt buffer (20 mM HEPES pH 7.9, 25%
glycerol, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM ethylenedi-
aminetetraacetic acid (EDTA), and 1 freshly added Com-
plete™ protease inhibitor tablet). Next, an equal volume
of a high-salt buffer (i.e. low-salt buffer plus 0.8 M NaCl)
was added, and the mixture left to stand on ice for 15
mins. [20]. Nuclear protein extracts were recovered by
centrifugation at 16,000 g for 15 mins.
Membrane protein extracts
Cells were washed three times with ice-cold PBS, centri-
fuged at 3,000 g for 5 mins, and the pellet resuspended in
0.5 ml of TEM A lysis buffer (20 mM Tris HCl pH 8.0, 0.5
mM EDTA, 0.5 mM EGTA, 10 mM 2-ME, and 1 freshly
added Complete™ protease inhibitor tablet), incubated
on ice for 5 mins, and then sonicated. Membrane protein
extracts were obtained by double sequential centrifuga-
tion of the lysis mixture, first at 1,000 g for 5 mins, then at
100,000 g for 30 mins for 250 µL of the supernatant. For
all the assays above, Bradford's assay (Bio-Rad, Hercules,
CA) was used to quantify protein concentrations in all
samples.
Western immunoblotting
Cell lysates (20.0 µg of protein/sample) were first resolved
on a 12.5% SDS-PAGE gel, transferred onto polyvinyli-
dene difluoride (PVDF) membranes (Millipore Corpora-
tion, Billerica, MA) and then blocked using Tris buffered
saline Tween-20 (TBST) buffer containing 5% non-fat
milk. Membranes were next hybridized overnight in the
cold room using various murine monoclonal antibodies
(mAb) – i.e. S10B1 anti-Ku86 N-terminus (amino acid
(aa) residues 8–221; NeoMarkers, Fremont, CA); anti-
heavy chain of the human major histocompatibility com-
plex (MHC) mAb (clone 22.63.4, Accurate Chemical and
Scientific Co., Westbuty, NY; a kind gift from P. Macary,
from the National University of Singapore); and anti-actin
(Santa Cruz Biotechnology, Santa Cruz, CA) mAbs;
washed three times in ice cold TBS-T; and then incubated
with horseradish peroxidase (hrp) conjugated anti-mouse
IgG mAb (1:2,000; Santa Cruz) for 1 hr. The reaction was
detected using the ChemiGlow chemiluminescence rea-
gents (Alpha Innotech, San Leandra, CA). Image spot den-
sitometry was performed on the Alpha Imager (Alpha
Innotech).
Electrophoretic mobility shift assay (EMSA)
Two 25-mer oligonucleotides; 5'-ACTTGATTAGTTACG-
TAACGTTATG-3' and 5'-CATAACGTTACGTAACTAAT-
CAAGT-3', with or without biotin labels at the 5' ends (1st
Base Pte Ltd., Singapore), were first annealed together (see
Pierce Technical Resource, TR0045.0, Pierce, Rockford,
IL). Standard EMSA reactions (Lightshift Chemilumines-
cent EMSA kit, Pierce) incorporated 4.0 µg of cell extract
and 20.0 fmol of biotin end-labeled DNA in a 20.0 µL vol-
ume binding reaction in the presence of 2.5% glycerol, 5
mM MgCl2, 50 ng/µL of poly(dI·dC), and 0.05% NP-40.
Unlabeled target DNA (4.0 pmol) was added per 20.0 µL
of binding reaction where indicated. Reactions were incu-
bated at room temperature for 30 mins and terminated by
adding 2.0 µL of 10× loading buffer (0.2% (w/v)
bromophenol blue and 0.2% xylene cyanol containing
10% (v/v) glycerol). Assays were loaded onto native 5%
polyacrylamide gels that were pre-electrophoresed for 60
mins in 0.5× Tris borate/EDTA buffer, resolved at 100 V,
and transferred onto nylon membranes (Hybond™-N+,
Amersham) in 0.5× Tris borate/EDTA buffer at 100 V for
30 mins. DNA was cross-linked (120 mJ/cm2) and
detected using hrp-conjugated streptavidin chemilumi-
nescence. Image spot densitometry was performed on the
Alpha Imager (Alpha Innotech).
Endoglycosidase H (EndoH) digestion
Endoglycosidase H resistance was assayed using the
EndoH digestion system (New England Biolabs, Ipswich,
MA) and performed according to the manufacturer's rec-
ommendations. Briefly, 30.0 µg of whole cell extracts were
denatured at 100°C for 10 mins using 1× glycoprotein
denaturing buffer, followed by addition of 1× G5 buffer
and 1.0 µL (500 units) of EndoH. The reaction mix was
incubated at 37°C; and at various time points, aliquots
were removed and resolved in a 12.5% SDS-PAGE gel for
carbohydrate (CHO) release.
Intracellular inhibition of protease digestion
In order to inhibit intracellular protease activity, 5 × 106
cells/sample were treated with: Complete™ protease
inhibitor tablets; either 1× (1 tablet for every 50 mL of
media) or 2× (2 tablets for every 50 mL of media); or
treated with antipain (2.0 µg/mL) plus leupeptin (2.0 µg/
mL) (both from Sigma-Aldrich, St Louis, MO, USA) for
cysteine protease inhibition; or aprotinin (2.0 µg/mL)
plus PMSF (100 µg/mL) (both from Sigma-Aldrich) for
serine protease inhibition; for to 24 hrs. Cell viability wasCancer Cell International 2008, 8:4 http://www.cancerci.com/content/8/1/4
Page 4 of 13
(page number not for citation purposes)
assessed by standard trypan-blue exclusion assays. Image
spot densitometry was performed on the Alpha Imager
(Alpha Innotech).
Cloning of Human Ku86 from RPMI cells
Full-length 2.4 kb Ku86 cDNA was obtained from total
RNA of RPMI 8226 MM cell lines by RT-PCR (Qiagen Inc.,
Valencia CA, USA). The primers used to amplify the Ku86
message were forward primer: 5' -TGTATGGACGT-
GGGCTTTACCAT-3' and reverse primer: 5' -TCCACAGA-
GAATTAGATGATCCGCC-3'. Purified Ku86 cDNA (2.4
kb) was then cloned into Topo-vector (Invitrogen) and
transformed into E. coli. The cloned Ku86 gene was fully
sequenced to confirm the insertion of full length 2.4 kb
Ku86 into the clone without any detected mutations
(BigDye™ Cycle Sequencing Kit, Applied Biosystems, Fos-
ter City, CA USA). In order to subclone the construct into
an mammalian expression system, two restriction enzyme
sites were engineered to the ends of cloned Ku86 gene
(HindIII at 5' end and XbaI at 3' end) by PCR of the clone
using high fidelity PWO SuperYield™ DNA polymerase
(Roche Diagnostics) and the following oligo's: Forward
oligo: 5'-
ATTAAAGCTTCCGGCAACATGGTGCGGTCGGGGAATA
AGGCAGCTGTTGTGCTGTGTATGGACGTGGGC-3' and
Reverse oligo: 5'ATTATCTAGACTTATCATGTCCAATA
AATC-3'. The engineered Ku86 was then subcloned into
the transient mammalian expression vector, pcDNA3.1/
myc-His B (Invitrogen). The purified plasmid (Ku86+
pcDNA3.1/myc-His B) was then transfected into mamma-
lian cell line (COS-7) for transient expression of Ku86
recombinant protein, using the Lipofectamine 2000™ rea-
gent (Invitrogen). Finally, the Ku86 recombinant proteins
were purified using ProBond™ Nickel-Chelating Resin col-
umn (Invitrogen) and detected using western
Immunblotting with anti-myc-HRP (Invitrogen) and/or
anti-Ku86 antibody (Neomarker).
Trypsin digestion of recombinant human Ku86 (rhKu86) 
protein
Full-length rhKu86 was first expressed and purified from
COS cells and digested (6.5 µg/sample or 13.0 µg/sample)
using trypsin (0.065 µg of Trypsin Gold/reaction,
Promega Corp. Madison, WI); at 100:1 protease:protein
ratio, in 50 nM acetic acid, pH 8.0, and 37°C, as recom-
mended at by the manufacturer (Promega Technical Bul-
letin, 309). The reaction was stopped by rapid freezing on
ice, and analyzed using SDS-PAGE and western immuno-
blotting.
Results and Discussion
Ku86 truncation is not the result of in vitro generated 
proteolysis in MM cell lines
Although a number of studies have characterized a 69-
kDa to 70-kDa truncated variant of Ku86 in vitro, a few
recent studies have suggested that this variant may be the
result of in vitro induced proteolysis during storage, han-
dling and lysis of B or T lymphocytes [21,22]. In this
present study, an SDS-PAGE whole cell lysis procedure, in
which all proteolytic activity is inhibited during isolation,
was used to demonstrate that RPMI 8226 and SGH-MM5
MM cells (Fig. 1A, lanes 5 and 6) contain a 69-kDa N-ter-
minus Ku86v despite the omission of the protein extrac-
tion steps and minimization of protease action. In
contrast, and in agreement with prior findings, human T
cells (samples from patient 1; Fig. 1A, lane 1) freshly iso-
lated from the PB did not display altered forms of Ku86.
Furthermore, CESS EBV-transformed B cell and K562
CML cell lines (Fig. 1A, lanes 2 and 3), which are known
to lack the expression of the 69-kDa variant of Ku86,
served as negative controls; and the HL-60 APL cell line
(Fig. 1A, lane 4), which is known to contain the 69-kDa
form of Ku86v, was used as a positive control for this
assay. These data suggest that the 69-kDa form of Ku86v
is generated in vivo, and is not likely to be an in vitro arti-
fact, in human MM cell lines.
In order to demonstrate in vitro proteolysis of Ku86, we
next analyzed protein extracts prepared using conven-
tional methods from previously frozen and stored cells
(Fig. 1B). Specifically, human T cells (samples from
patients 2 and 3), CESS and the K562 cell lines, that lack
69-kDa Ku86v expression (Fig. 1B, lanes 1 to 4); were
compared with the HL-60 cell line, which is known to
express 69-kDa Ku86v, RPMI 8226, and SGH-MM5 MM
cell lines (Fig. 1B, lanes 5 to 7). In this experiment, both
human T cells, as well as the CESS and K562 cell lines not
only contained 69-kDa Ku86v, but also various other frag-
ments of Ku86. Moreover, even HL-60, RPMI 8226 and
SGH-MM5 cell lines, that constitutively express 69-kDa
Ku86v, also contained numerous Ku86 fragments. These
data suggest that freezing and storage of cells leads to
extensive in vitro proteolysis of cellular proteins. Further-
more, whole cell extracts from the RPMI 8226 cell line,
which were made in a protease-free extraction buffer, i.e.
either extraction buffer plus 1× Complete™ tablet (Roche
Diagnostics) and 1× PMSF, or extraction buffer plus 2×
Complete™ tablets and 2× PMSF, demonstrated no change
in the expression of the Ku86 variant or its full-length
form (data not shown). Collectively, these data confirm
that although proteases released during isolation proce-
dures can lead to extensive Ku86 degradation in vitro,
truncated forms of Ku86 in RPMI 8226 and SGH-MM5
MM cell lines are more likely to have been generated in
vivo and constitutively.
The 69-kDa Ku86v in MM cell lines are present in the 
cytosolic, nuclear and membrane fractions and binds DNA
Since CD40 activation of MM cell lines results in the
membrane expression of Ku86 in MM cells [6,12,12], weCancer Cell International 2008, 8:4 http://www.cancerci.com/content/8/1/4
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also investigated the distribution of 69-kDa Ku86v in var-
ious subcellular locations, i.e. cytosol, nucleus and cell
membrane, relative to CD40 triggering. As can be seen in
Fig. 2A, 69-kDa Ku86v is present in all subfractions but is
at higher (2.5-fold) levels in the cytosol after CD40 trig-
gering of the RPMI 8226 MM cell line. In order to define
a functional role for this observation, we analyzed the
DNA-binding characteristics of Ku86 and Ku86v to a
known 25-bp Ku86 binding DNA oligonucleotide using
EMSAs (Figs. 2B and 2C) [16,22], in CD40-triggered RPMI
8226 MM cells in various subcellular fractions. We dem-
onstrate binding of DNA to both 86-kDa Ku86 (band
position I) as well as 69-kDa Ku86v (band position II);
confirming the presence of these proteins in the RPMI
8226 MM cell line. In contrast, only full-length Ku86 was
found in the negative control CESS cells. Similar results
were obtained for the SGH-MM5 MM cell line (data not
shown). Interestingly, no other bands are detected sug-
gesting that if other forms of Ku86 exist they do not bind
DNA. Moreover, cold competitor DNA was used to con-
firm specificity of the 25-bp oligonucleotide for Ku86
binding (Fig. 2C). Since the DNA binding domain of
Ku86 is located in the N-terminus and is preserved in both
full-length Ku86 as well as the 69-kDa Ku86v, our data
not only confirms the presence of truncated Ku86v, but
also suggests a functional role for Ku86v.
Surprisingly, triggering of MM cells via CD40 had no
effect on the amount of 86-kDa Ku86 protein bound to
DNA in all cellular subfractions (Fig. 2B, band position I)
isolated from RPMI 8226 cells and well as SGH-MM5 MM
cell line (data not shown). By contrast, binding of 69-kDa
Ku86 truncation is not the result of in vitro generated proteolysis in human MM cell lines Figure 1
Ku86 truncation is not the result of in vitro generated proteolysis in human MM cell lines. Immediate whole cell 
lysis (5.0 × 106 cells/sample) was performed on freshly-obtained human PB T cells (sample from patient 1), CESS, K562, HL60, 
and RPMI 8226 and SGH-MM5 MM cell lines using a denaturing and reducing gel-loading buffer (95°C for 10 mins) (A). Cell 
extracts were also prepared using conventional methods from previously frozen and stored human PB T cells (samples from 
patients 2 and 3), K562 CML, and HL60, and RPMI 8226 and SGH-MM5 MM cell lines (B). Cell lysates (20.0 µg/sample) were 
resolved on a 12.5% SDS-PAGE gel, transferred onto PVDF membranes, and probed with S10B1 anti-Ku86 mAb, which recog-
nizes the N-terminus of Ku86. Membranes were stripped and re-probed using anti-actin mAb (control) to confirm equal pro-
tein loading. Experiments were performed in triplicate.Cancer Cell International 2008, 8:4 http://www.cancerci.com/content/8/1/4
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The 69-kDa Ku86v in MM cell lines is present in the cytosolic, nuclear and membrane fractions and binds DNA Figure 2
The 69-kDa Ku86v in MM cell lines is present in the cytosolic, nuclear and membrane fractions and binds DNA. 
Having determined that MM cell lines constitutively express 69-kDa Ku86v, we next studied the subcellular location of Ku86v. 
Moreover, since CD40 triggering induces expression of 86-kDa Ku86 on the cell membrane of MM cells, we also investigated 
whether CD40 triggering affected the subcellular location Ku86v. Fresh whole cell (W), cytosolic (C), nuclear (N) and mem-
brane (M) cell lysate fractions were obtained from sCD40L-triggered (5.0 µg/mL for 4 hrs) and resting RPMI 8226 MM cells, 
and subjected to normal SDS-PAGE (A). Full-length and variant forms of Ku86 were detected by western immunoblotting using 
S10B1 anti-Ku86 mAb. Membranes were stripped and re-probed using anti-actin mAb (control) to confirm equal protein load-
ing. Relative expression of 69-kDa Ku86v (normalized to weakest band) was determined using image densitometry and 
expressed in bar chart format. The presence of Ku86/Ku86v protein-DNA complexes were next detected using EMSA (B and 
C). Cytosolic (C), nuclear (N) or membrane (M) protein extracts (4.0 µg/sample) were first obtained from CESS (negative con-
trol), CD40-triggered (5.0 µg/mL sCD40L for 4 hrs) or non-CD40-triggered RPMI 8226 MM cell lines. Non-competitive bind-
ing of Ku86/Ku86v to DNA (B) was detected using a specific biotin end-labeled DNA probe (20.0 fmol/sample), native PAGE, 
and hrp-conjugated streptavidin chemiluminescence imaging. Full-length Ku86-DNA complexes are found at position I, whereas 
DNA complexes with the truncation variant of Ku86 are found at position II. Relative expression of 69-kDa Ku86v-DNA com-
plexes (normalized to weakest band) was determined using image densitometry. To confirm the specificity of DNA binding, a 
competitive assay (C), in which a variable amount of cell lysate (up to 5.0 µg/sample) was mixed with a fixed amount (4.0 pmol/
sample) of non-biotin-labeled DNA, was also performed in the same fashion. All experiments were repeated with the SGH-
MM5 MM cell line (data not shown), showed similar results, and performed in triplicate.Cancer Cell International 2008, 8:4 http://www.cancerci.com/content/8/1/4
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Ku86v to DNA was constitutively greater in the cytosol
and cell membrane, but not in the nucleus (Fig. 2B, band
position II); suggesting that 69-kDa Ku86v could be func-
tionally different in different cellular compartments.
Binding of DNA to 69-kDa Ku86v in both the cytosol and
cell membrane is increased following CD40 triggering of
RPMI 8226 MM cell lines; suggesting that CD40 triggering
could induce the DNA-binding activity of Ku86v. This
increased binding following CD40 triggering is not
accompanied by increased amount of Ku86v expression
in the nuclear fraction, as the levels are similar before and
after CD40 triggering (Fig. 2A). Whereas this appears to be
true for cell membrane Ku86v, expression of 69-kDa
Ku86v in the cytosol is increased by approximately 2.5-
fold after CD40 triggering (Fig. 2A), suggesting that
increased sequestration or recruitment of 69-kDa Ku86v
to the cytosol, rather than an increase in the DNA-binding
activity of Ku86v, could be the more probable reason for
these observations. This data is in contrast to a previously
published report that shows a predominant Ku86 variant
DNA-binding complex in nuclear extracts of human lym-
phocytes [20] and suggests that MM cells have a unique
pattern of Ku86 distribution.
69-kDa Ku86v in MM cell lines is not the result of 
alternative splicing of RNA or post-translational 
modification by N-linked deglycosylation
Since 69-kDa Ku86v in MM cell lines does not result from
proteolytic cleavage during cell lysis, we asked whether
the RNA transcript arose through alternative splicing. As
was reported in other studies, [5,16] northern blotting
demonstrated only two RNA transcripts of 3.4 kb and 2.6
kb length in RPMI 8226 and SGH-MM5 MM; K562 (neg-
ative control); and HL-60 (positive control) cell lines
(data not shown). Moreover, the larger 3.4 kb RNA tran-
script contains both the 5' and 3' regulatory untranslated
material [24,25] as well as the typical translated product.
These data concur with previously published data and
suggest that both RNA transcription and splicing are nor-
mal in RPMI 8226 and SGH-MM5 MM cell lines. Moreo-
ver, CD40 activation did not appear to affect RNA
transcription and splicing of Ku86 (data not shown).
Since post-translational modifications can also generate
truncated protein variants, and numerous proteins in MM
cells have been found to be heavily glycosylated [26-28],
we studied the post-translational carbohydrate modifica-
tions of Ku86 and Ku86v proteins in order to determine
whether the 69-kDa Ku86v is the result of post-transla-
tional degycosylation. As can be seen in Fig. 3A, neither
short term (2 hrs) nor long term (24 hrs) EndoH treatment
resulted in a decrease of 69-kDa Ku86v and concomitant
increase of 86-kDa Ku86; suggesting that truncated Ku86v
was not the result of N-linked deglycosylation of the 86-
kDa Ku86 [29]. By contrast, EndoH treatment induced a
faster migrating form of the 44-kDa heavy chain of the
human (MHC) class I protein (Fig. 3B), which is known
to be heavily glycosylated in the endoplasmic reticuculum
[30,31].
Proteolysis plays an important role in the intracellular 
generation of 69-kDa Ku86v in MM cell lines
In order to investigate other post-translational modifica-
tions that might be responsible for the generation of 69-
kDa Ku86v, we looked at the intracellular proteolytic deg-
radation of Ku86. Since our current data (Fig. 1B and 2A)
have demonstrated that various in vitro protease inhibi-
tion strategies using fresh cell lysates did not reduce the
generation of 69-kDa Ku86v, we investigated the effects of
various inhibitors in whole MM cells. Within the MM cell,
the ubiquitin-proteasome pathway is amongst the most
active intracellular protein degradation systems. Surpris-
ingly, incubation of whole MM cells with 2 to 24 ng/mL
of bortezomib (Velcade®, Millennium Pharmaceuticals,
MA, USA), a proteasome inhibitor, for as much as 48 hrs,
had no effect on proteolytic generation of Ku86 or Ku86v
(data not shown); suggesting that other proteolytic sys-
tems could be active in the MM cell. However, simultane-
ous inhibition of several classes of proteases; namely
serine, cysteine and metallo- proteases using Complete™
tablets for 18 hrs was associated with 3- to 7-fold
decreased expression of 69-kDa Ku86v (Fig. 4A lanes 2
and 3), as compared to the mock experiment (Fig. 4A lane
1). The data again suggest that 69-kDa Ku86v is generated
constitutively within living MM cells. Similarly, broad-
based inhibition of serine proteases via aprotinin plus
PMSF (Fig. 4B lane 4), but not inhibition of cysteine pro-
teases via antipain plus leupeptin (Fig. 4B lane 3), for 24
hrs is associated with 3- to 4-fold decreased expression of
69-kDa Ku86v; further suggesting that serine proteases
(but not cysteine proteases) could be involved in genera-
tion of 69-kDa Ku86v. Importantly, protease inhibition
did not affect cell viability (data not shown), or expres-
sion of 86-kDa Ku86 or actin. These data are consistent
with a report that suggests that nuclear serine proteases are
responsible for in vitro generated forms the Ku86 variant
[22].
Trypsin generates a 69-kDa Ku86 variant protein from a 
full-length cloned human MM Ku86 protein (rhKu86) in 
vitro
In order to specifically test whether the 69-kDa Ku86v
protein could be a result of protease digestion of full-
length 86-kDa Ku86, we first cloned full-length human
Ku86 from MM cell lines and produced full-length recom-
binant human Ku86 (rhKu86) in COS cells. During the
purification of the 6-histadine-tagged rhKu86 protein
from COS cells complexes of around 220-kDa were
observed in the flow through and whole cell extracts, but
in the eluted concentrated rhKu86 protein fraction, no
higher order complexes were observed (data not shown).Cancer Cell International 2008, 8:4 http://www.cancerci.com/content/8/1/4
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69-kDa Ku86v in MM cell lines is not the result of post-translational modification by N-linked deglycosylation Figure 3
69-kDa Ku86v in MM cell lines is not the result of post-translational modification by N-linked deglycosylation. 
Freshly obtained cell lysates (30 µg/sample) from the SGH-MM5 MM cell line were incubated with or without EndoH (500 U/
reaction) for 2 hrs or 24 hrs (A); or with varying amounts (0, 1, 2, 3, 4 or 5 µL) of EndoH (500 U/µL) for 20 hrs (B; positive 
control); and then resolved in a 12.5% SDS-PAGE gel, and immunoblotted using S10B1 anti-Ku86 (A), or anti-heavy chain of the 
human MHC class I protein mAbs (B). Membranes were stripped and re-probed using anti-actin mAb (control) to confirm 
equal protein loading. Experiments were performed in triplicate.Cancer Cell International 2008, 8:4 http://www.cancerci.com/content/8/1/4
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Proteolysis plays an important role in the intracellular generation of the 69-kDa Ku86v variant protein in MM cell lines Figure 4
Proteolysis plays an important role in the intracellular generation of the 69-kDa Ku86v variant protein in MM 
cell lines. RPMI 8226 (A) and SGH-MM5 (data not shown) MM cell lines (5.0 × 106 cells/sample) were first incubated for 18 
hrs with either 1× or 2× Complete™ protease inhibitor tablets (lanes 2 and 3); and then washed and checked for viability using 
trypan blue exclusion assay. Mock experiments in which cell lines were incubated for 18 hrs with media alone (lane 1) served 
as negative controls. Cell lysates were resolved by SDS-PAGE and immunoblotted using S10B1 anti-Ku86 mAb. The RPMI 8226 
MM cell line s (B) was also incubated for 24 hrs with 2× Complete™ protease inhibitor tablets (lane 2), antipain (2.0 µg/mL 
final concentration) plus leupeptin (2.0 µg/mL final concentration) (lane 3), or aprotinin (2.0 µg/mL final concentration) plus 
PMSF (100 µg/mL final concentration) (lane 4) and analyzed in the same way as above. Mock experiments in which cell lines 
were incubated for 24 hrs with media alone (lane 1) again served as negative controls. Membranes were stripped and re-
probed using anti-actin mAb (control) to confirm equal protein loading. Cell lysates were resolved by SDS-PAGE and immuno-
blotted using S10B1 anti-Ku86 mAb. Relative expression of 69-kDa Ku86v-DNA complexes (normalized to weakest band) was 
determined using image densitometry. All experiments were performed in triplicate.Cancer Cell International 2008, 8:4 http://www.cancerci.com/content/8/1/4
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This suggests that most of the Ku86 protein does not asso-
ciate with monkey Ku70 and is likely due to the large
excess of cloned human Ku86 to that of the endogenous
monkey Ku70 proteins. Thus, this synthetic protein is
likely to exist as homodimer, lacks stabilization by its
usual molecular partner, Ku70, and probably undergoes
some spontaneous degradation in this expression system
(Fig. 5A lane 1). As can be seen in Fig. 5A lane 2, trypsin
digestion rapidly (within the first minute) reduced the
amount of 86-kDa rhKu86 and increased the proportion
of a 69-kDa Ku86 fragment. By the third minute (Fig. 5A
lane 3) other smaller fragments of Ku86 have also
appeared. Digestion continues over several mins, and by
20 mins., almost the entire original 86-kDa rhKu86 as
well as the 69-kDa proteins have been digested (Fig. 5A
lanes 4–7). These data suggest that trypsin-like proteases
could preferentially generate a 69-kDa fragment of Ku86
protein. Accordingly, to determine if protease inhibitors
could now inhibit the generation of this protein, we per-
formed trypsin digestion of rhKu86 without (Fig. 5B lane
1) or with (Fig. 5B lane 2) protease inhibitors (aprotinin
plus PMSF). We demonstrate that protease inhibition is
very effective in inhibiting breakdown of 86-kDa rhKu86;
but as expected, protease inhibition is not complete and
some smaller fragments are formed. However, the further
degradation of Ku86 is virtually inhibited. These data con-
firm that trypsin-like activity is likely to contribute (at
least in part) to the degradation of Ku86 into a 69-kDa
variant form.
Conclusion
Karyotypic analysis of tumor cells from patients with MM,
as well as MM cell lines, frequently demonstrates numer-
ous complex chromosomal abnormalities. Moreover, new
chromosomal translocations into the switch region of the
immunoglobulin heavy chain (IgH) gene (chromosome
14q32) often heralds transformation to more aggressive
MM [23] Since DNA DSBR is important in mediating
these processes, this suggests that abnormalities in DSBR
could ultimately lead to genomic instability, clonal evolu-
tion and disease progression in MM. Truncated variants of
Ku86 protein (i.e. Ku86v) have previously been detected
in 86% to 100% of freshly isolated patient MM cells [5].
However, since the expression of an altered form of the
Ku86 protein in B cells [16] has been recently challenged
[21]. as perhaps being non-physiological, we carefully
investigated the presence of truncated forms of Ku86. The
presence of the 69-kDa truncated form of Ku86 detected
by antibodies directed against the N-terminus part of the
protein was confirmed in both traditional western blots as
well as direct lysate fresh whole cell western immunoblot-
ting.
In agreement with previously published data that the C-
terminus truncated Ku86 variant from MM cells binds
double stranded DNA ends [5], we show DNA end-bind-
ing (DEB) activity with both the full-length and truncated
variant of Ku86 in all cellular subfractions tested. This is
consistent with the 69-kDa variant of Ku86 that was
found in mammalian mitochondria that still associates
with DNA and is found in a complex with Ku70 [19].
Since the DNA binding motifs of Ku86 are located in the
N-terminus, and the functional domains are located in the
C-terminus, these data support the notion that while
Ku86v-C binds DNA, it is in fact incapable of regulating
DNA repair. This is further supported by published data
that demonstrated the heteroduplex of Ku70 and Ku86
variant bind DNA-PKcs less well than those containing
full-length Ku86 [5] and are deficient in DNA-PK activity
[16]. The link between the defective DNA-PK activity as a
result of Ku86 variant and Ku70 heteroduplex formation
and genomic instability in MM has not been proven thus
far, although cells expressing Ku86 variants do display
increased sensitivity to DNA damage [5,16,17]. The ability
of multiple myeloma-specific Ku86 variant protein to
bind Ku70 or itself and to activate DNA-PK and its overall
effect on DNA repair in MM cells is the subject of ongoing
work.
Since protease digestion of DNA-PK and Ku proteins are
enhanced by proteasome inhibition (i.e. bortezomib
treatment) in MM cell lines [32] these data taken in aggre-
gate further suggest that proteolytic enzymes that are capa-
ble of digesting Ku proteins are constitutively activated,
and possibly accumulate and/or become further activated
under proteasome inhibition in MM cells. Thus, the
observed trypsin-like serine protease-dependent cleavage
of Ku86 during the isolation procedures [22] may in fact
operate naturally in intact MM cells. These findings, as
well as those that found that modification of Ku86 can
occur with viral infections, phorbyl ester, and calcium
phosphate treatment in CV1 cells [33], suggest that under
certain conditions or in certain cells lines Ku86 truncation
may occur in a non-inducible proteolytic-dependent fash-
ion. Our data suggests that these potential proteases may
be acting in the cell naturally and perhaps in a constitutive
fashion in MM cells. Serine protease inhibition is much
more effective than cysteine protease inhibition in reduc-
ing the appearance of the Ku86 variant in whole RPMI
cells (Fig. 4B). Using rhKu86 and in vitro limited diges-
tion, one likely candidate may be trypsin (Fig. 5). In fact,
by looking at the sequence of Ku86 and using bioinfor-
matics approach we were able to narrow down potential
digestion of Ku86 into 20 different proteases (using the
Peptide Cutter Peptide Characterization software-
ExPASy, Swiss Institute for Bioinformatics). Trypsin, chy-
motrypsin and other serine proteases putatively cleave
Ku86 in multiple locations. However, finding the exact
physiologically relevant protease that generates the vari-
ant in vivo will require more detailed analysis. We haveCancer Cell International 2008, 8:4 http://www.cancerci.com/content/8/1/4
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only partially attempted to address this by using protease
inhibitor in living cells. At the doses used, antipain and
leupeptin are more selective towards cysteine inhibition
than towards inhibition of serine proteases and aprotinin
and PMSF are powerful serine protease inhibitors. How-
ever, it is important to note that there is likely to be some
cross-inhibition. Thus, other studies using various single
and multiple cysteine and serine protease inhibitors as
well as mettaloproteinase inhibitors such as TIMP-2, will
be needed to more closely address this issue. However,
this study as well as two others, [18,22] suggest that serine
proteases are likely to be important for the generation of
the 69-kDa form of Ku86. However, our studies as well as
others investigate Ku86 and its variant in conditions that
do not allow for the association with Ku70. It is well
known that Ku86 is most effective in binding DNA and
recruiting DNA repair enzymes when it is heterodimer-
ized with Ku70 which occurs via the C-terminus of both
proteins [34]. We are interested in determining the natu-
rally occurring proteolytic cleavage site of Ku86 and to
examine how it affects hetero-complex formation. We
hypothesize that a fraction of newly synthesized Ku86
protein is immediately and constitutively cleaved by pro-
teases into a Ku86 69-kDa form that would prevent it
from tight association with Ku70.
The localization of Ku86 within different compartments
within the cell is likely to be of significant importance in
B cell DNA repair and perhaps in the regulation of
genomic stability of MM cells. In fact, the intracellular
trafficking of Ku protein to extranuclear sites has been sug-
gested to play important role in numerous non-DNA
repair Ku-associated functions [7,13] Importantly, the
localization of Ku to the membranes of MM cells follow-
ing sCD40L treatment leads to increased adhesion to
bone marrow stromal cells and interneukin-6 (IL-6) pro-
duction [12]. These and other studies prompted us to
thoroughly examine the localization of Ku86 and Ku86
variant in the nucleus, cytosol and membrane of MM cells
before and after CD40 stimulation. Unexpectedly, there
were little differences observed in each of the cellular frac-
tions for the full-length Ku86 protein levels in MM cells.
Contrary to previously published data that shows
increased Ku86 truncation variant in the nuclear fraction
of human PBMC [22], we found equal levels of the Ku86v
in the membrane, nuclear and cytosolic fractions in
Trypsin digestion generates a 69-kDa Ku86 protein from a full-length cloned human MM Ku86 protein (rhKu86) in vitro Figure 5
Trypsin digestion generates a 69-kDa Ku86 protein from a full-length cloned human MM Ku86 protein 
(rhKu86) in vitro. Full-length rhKu86 was first expressed and purified from COS cells. Serial digestion (A) of rhKu86 (6.5 µg/
sample) by trypsin (0.065 µg of Trypsin Gold/reaction up to 20 mins) was then performed using a limited proteolysis protocol 
from the manufacturer. The reactions were stopped by rapid cooling on ice; and the products of trypsin digestion were 
resolved by SDS PAGE and immunoblotted S10B1 anti-Ku86 mAb. The effect of protease inhibitors aprotinin (2.0 µg/mL final 
concentration) plus PMSF (100 µg/mL final concentration) on trypsin digestion was also determined on a larger sample of 
rhKu86 (13.0 µg/sample). Trypsin digestion (0.065 µg of Trypsin Gold/reaction for 1 min) of rhKu86 was performed as above 
either without (lane 1) or with (lane 2) protease inhibitors (B).Cancer Cell International 2008, 8:4 http://www.cancerci.com/content/8/1/4
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unstimulated MM cells. Yet, when the cells were stimu-
lated with sCD40L, we did observe an increased amount
of Ku86 variant in the cytosol accompanied by an increase
in the DNA binding activity of Ku86v in the cytoplasm
and not in the nucleus. These findings may be due to the
cell type or to the fact that there appears to be little to no
in vitro generated protease cleavage of Ku86 occurring dur-
ing our biochemical preparations. However, the nature of
the truncation is still unknown and unlikely due to post-
transcriptional modification or carbohydrate modifica-
tion. We are currently using more sensitive techniques of
isolating various cellular fraction, performing 2-dimen-
sional gel electrophoresis, and mass spectrometry, as well
as Edmund degradation to try and determine the exact
nature of this MM-specific Ku86 truncation variant. We
are also currently performing studies to determine the
biological function of the variant and how it might inter-
act or disrupt the normal Ku86/Ku70/DNA-PKcs holoen-
zyme. Finally, we routinely see both the full-length and
the truncation variant in all of our cell fractions and have
not seen a time-dependent reduction in the amount of
full-length Ku86 nor an increase in the variant Ku86
under any conditions. We therefore believe that the vari-
ant seen in MM cell lines is regulated in a distinct fashion
from the Ku86 truncation variant that is seen in PBMCs.
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